to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)

Phase 2CompletedNCT02008929

Samsung Medical Center5 enrolled

Overview

To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.

To see the safety and efficacy of injecting MG4101(Ex vivo expanded allogeneic NK cell) as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatocellular Carcinoma

Interventions

MG4101BIOLOGICAL

Ex vivo expanded allogeneic NK cell

Eligibility

Sex: ALLMin age: 20 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Under the age of 20 to 69 years of age 2. Child-pugh class A 3. After curative liver resection, diagnosed hepatocellular carcinoma 4. Modified UICC staging : stage 3 5. the women who is childbearing age, agree to maintain adequate contraception measure during clinical trial period. 6. Agreed to participate in this clinical trial, agree to the subject person or legal representative who agrees in writing Exclusion Criteria: 1. Less than 20 years old, 70 years old or older 2. Metastasis of hepatocellular carcinoma with external parties surgery 3. who had Rupture of hepatocellular carcinoma (HCC) 4. Hepatocellular carcinoma treated with radiofrequency surgery therapeutics (Radiofrequency ablation, RFA), the carotid artery chemical embolization (Transarterial chemoembolization, TACE), underwent radiation therapy, such as topical therapeutics 5. suspected serious infection 6. Who have severe cardiovascular disease (coronary artery disease requiring treatment, heart failure, arrhythmias, myocardial infarction, etc.) 7. Pregnant, planning a pregnancy or breast-feeding women 8. Autoimmune Disease 9. Those who Latest within four weeks of administration of systemic steroids (However, inhalation, intranasal corticosteroids and topical administration of corticosteroids and short-time administration of a blood transfusion, if such reasons are excluded) 10. Latest within four weeks of taking immunosuppressive drugs such as Cyclosporine A 11. Within the last 5 years diagnosed with liver cancer and other malignancies 12. Investigator did not complete or the effectiveness or safety of pharmaceutical products of this clinical trial evaluation for any medical condition that can interfere with characters judged

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Disease free survival, DFS

As of Date for allocation to survival and recurrence of the incident or death from any cause is defined as. 1 year disease-free survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.

Time frame: Disease free survival for 1year

Secondary Outcomes

Changes in tumor markers

Basaline(V2) at each visit compared (V6, V8, V9, V10) with respect to variation in average by descriptive statistics (mean, standard deviation, median, minimum, maximum) and presented, in comparison to the group in order Paired t-test or the Wilcoxon's signed rank test for analysis.

Time frame: Changes in tumor markers. to be specific, alpha-fetoprotein(AFP), protein induced by vitamin K absence- II(PIVKA-II)

Overall survival, OS

As of Date for allocation to survival, and the incident was defined as death from any cause. 1 year overall survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.

Time frame: Overall survival, OS at the end point of clinical trial

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.